Inventor · disambiguated record
Dennis Zaller
Also filed as: ZALLER DENNIS · ZALLER DENNIS M · ZALLER DENNIS MICHAEL
12 granted patents·13 pending applications·469 citations·filing 2000–2024
91Inventor score
Top patents by PatentIndex Score
25 records- 0196US6498165B1Src kinase inhibitor compoundsMERCK & CO INC·Filed 2000·Granted Dec 24, 2002·238 cites·39 claims
- 0295US6316444B1SRC kinase inhibitor compoundsMERCK & CO INC·Filed 2000·Granted Nov 13, 2001·120 cites·41 claims
- 0393US6329380B1SRC kinase inhibitor compoundsMERCK & CO INC·Filed 2000·Granted Dec 11, 2001·87 cites·41 claims
- 0491US7754213B2High affinity antibody antagonists of interleukin-13 receptor alpha 1MERCK & CO INC·Filed 2007·Granted Jul 13, 2010·13 cites·7 claims
- 0584US11510993B2Antibody drug conjugate for anti-inflammatory applicationsMERCK SHARP & DOHME·Filed 2016·Granted Nov 29, 2022·3 cites·20 claims
- 0679US9371388B2High affinity antibody antagonists of interleukin-13 receptor alpha 1CSL LTD·Filed 2013·Granted Jun 21, 2016·2 cites·4 claims
- 0777US2025145654A1Compounds and methods for treating diseaseROME THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 0876US9777062B2High affinity antibody antagonists of interleukin-13 receptor alpha 1CSL LTD·Filed 2016·Granted Oct 3, 2017·1 cites·10 claims
- 0976US8568722B2High affinity antibody antagonists of interleukin-13 receptor alpha 1NASH ANDREW DONALD·Filed 2010·Granted Oct 29, 2013·2 cites·2 claims
- 1074US12187758B2Compounds and methods for treating diseaseROME THERAPEUTICS INC·Filed 2023·Granted Jan 7, 2025·0 cites·26 claims
- 1174US8207304B2Antibody antagonists of interleukin-13 receptor α1NASH ANDREW DONALD·Filed 2007·Granted Jun 26, 2012·2 cites·6 claims
- 1271US8613925B2Anti-IL-13Rα1 antibodies and their uses thereofNASH ANDREW DONALD·Filed 2007·Granted Dec 24, 2013·1 cites·9 claims
- 1369US2023295212A1Compounds and methods for treating diseaseROME THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 1469US2023099074A1Antibody drug conjugate for anti-inflammatory applicationsMERCK SHARP & DOHME LLC·Filed 2022·Application pending·0 cites
- 1564US10106617B2High affinity antibody antagonists of interleukin-13 receptor alpha 1CSL LTD·Filed 2017·Granted Oct 23, 2018·0 cites·12 claims
- 1661US2025161359A1Proteinase 3 (pr3) chimeric autoantibody receptor t cells and related methods and usesJUNO THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 1760US2025282803A1Didehydro-3'-deoxy-4'-ethynylthymidines and related compounds and their use in treating medical conditionsROME THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 1858US2025186475A1Methods of treating medical conditions using islatravir or a related compoundROME THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 1958US2025186467A1Methods of treating medical conditions using stampidine or a related compoundROME THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 2057US2025170158A1Methods of treating medical conditions using censavudine or a related compoundROME THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 2155US2025268925A1Methods of treating medical conditions and inhibiting line1 reverse transcriptase using a substituted adeninyl-propyloxy phosphonic acid or related compoundROME THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 2254US2024366649A14-ethynyl-3-hydroxy-tetrahydrofuranyl-adenine phosphoramidates and related compounds and their use in treating medical conditionsROME THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 2354US2024261317A1Methods of treating medical conditions and inhibiting line1 reverse transcriptaseusing a substituted 4-fluoro-2,5-dihydrofuranyl phosphonic acid or related compoundROME THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 2447US2024052064A1Anti-bcma therapy in autoimmune disordersBRISTOL MYERS SQUIBB CO·Filed 2021·Application pending·0 cites
- 2544US2005165232A1Phenyl substituted imidaopyridines and phenyl substituted benzimidazolesFiled 2003·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Dennis Zaller files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →